Navigation Links
Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
Date:3/1/2013

SAN FRANCISCO, March 1, 2013 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) Senior Vice President and Chief Medical Officer, Dr. Robert Medve , is scheduled to present at the 33rd Annual Cowen and Company Healthcare Conference at the Boston Marriott Copley Place on Tuesday, March 5, 2013 at 8:00 a.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website http://www.nektar.com. This webcast will be available for replay until April 8, 2013.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in pain, oncology and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which has completed Phase 3 clinical development as a once- daily, oral tablet for the treatment of opioid-induced constipation. This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid. In the proprietary pipeline, NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain. NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers.

'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... the leading innovation partner to companies worldwide , ... and anticipates the creation of over 350 new jobs through ... In 2013, the State of Ohio ... to accelerate adoption of open innovation among Ohio ... revenues. To date over 45 middle market companies have worked ...
(Date:8/27/2015)... Mass. and TORONTO , ... ) (OTCQB: GNBT) today announced the issuance of a ... Company,s proprietary buccal insulin spray product.  The white paper ... of the Company,s stockholders by Dr. James H. ... The white paper may be viewed online on the ...
(Date:8/27/2015)... Calif. , Aug. 27, 2015  Mytrus, a technology and ... software platform for electronic informed consent has received approval ... Health Service (NHS). It is the first time e-Consent ... England . Mytrus was ... use in a clinical trial by the U.S. Food ...
Breaking Medicine Technology:State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 2State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 3Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 5Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 6Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 7
(Date:8/27/2015)... OK (PRWEB) , ... August 27, 2015 , ... ... I, LP portfolio company and leading biopharmaceutical contract development manufacturing company (CDMO), announced ... Hepalink USA Inc. (“Hepalink”) for $205.68M in cash. , The addition ...
(Date:8/27/2015)... ... ... Florida Hospital North Pinellas, located at 1395 South Pinellas Avenue in Tarpon Springs, will open ... will be located at US Highway 19 North and Highlands Boulevard, less than eight miles ... on the project is slated to begin in September 2015. , The new ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Sunbelt® Bakery, ... high fructose corn syrup, is changing the expectation of how protein bars should taste ... indulgent taste unlike any other protein bar on the market today. , The ...
(Date:8/27/2015)... ... August 27, 2015 , ... Catalent ... for drugs, biologics and consumer health products, today announced that Ms. Esther Sadler-Williams, ... to be held at the Radisson Blu Edwardian Hotel, London Heathrow, on September ...
(Date:8/27/2015)... (PRWEB) , ... August 27, ... ... an executive management consulting firm that helps libraries, publishers and companies leverage ... Service Provider (RSP) for the VIVO Project. Gunter Media Group, Inc., will ...
Breaking Medicine News(10 mins):Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 2Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 3Health News:Clinical Trial Supply Chain Logistics to be Discussed By Catalent Expert at Upcoming Flypharma Conference 2Health News:DuraSpace Selects Gunter Media Group, Inc. as a Registered Service Provider for VIVO 2Health News:DuraSpace Selects Gunter Media Group, Inc. as a Registered Service Provider for VIVO 3
... Government medical services in Andhra Pradesh came to ... indefinite// strike enters the second day. ,Patients ... emergency services. Patients seeking immediate medical assistance had ... prevailed at the Osmania General Hospital and the ...
... about the hearing loss caused by the MP3 players, ... paying// any heed to those warnings. But sensing the ... limiting the volume on the devices. ,The American ... to the ears associated with MP3 players. The ASHA ...
... A relatively new kind of antibiotic has been found to ... is necessary// before the drug can be prescribed, says a ... around the world, causes inflammation of the airways, or bronchi, ... thereby disrupting breathing. ,During an asthmatic attack, the ...
... Special K Snack Bites are Kellogg’s latest additions to ... on-the-go consumer//. ,The Granola Munch'ems snack bites ... and minerals such as Vitamin A, Vitamin B6, Thiamin, ... available as bite-sized-morsels in individual pouches which are available ...
... new research, men who have elevated levels of testosterone ... but may lead shorter lives// when compared with men ... ,According to foodconsumer.org, comparative studies have studied testosterone levels ... very few studies have attempted to relate testosterone to ...
... of Prestbury Avenue, Newcastle-under-Lyme, Staffs, was found not guilty of ... the manslaughter of a baby who died of head injuries ... Crown Court took five hours to reach their verdict. Passing ... the family. ,Dr El-Khadem an Egyptian by birth ...
Cached Medicine News:Health News:Doctors Strike In Andhra Enters The Second Day 2Health News:Sensing The Health Hazard MP3 Makers Tone Down The Volume 2
... Packed conveniently in plastic-wrapped racks of ... to useno need to autoclave. Sterilized Diamond ... efficient sterilization and are delivered with a ... irradiation. Sterilized Diamond Tips are certified free ...
... Finntips have been designed to optimize ... quality of our tip products is widely ... Finntip range has been extended over the ... of standard and special tips including filter ...
MBP's 200 L large orifice tip is perfect for handling fragile cells, viscous samples and genomic....
The BioCheck LH ELISA is intended for the quantitative determination of luteinizing hormone (LH) in human serum. This assay is useful in the diagnosis and treatment of gonadal dysfunction....
Medicine Products: